Cellex is a Germany-based end-to-end CDMO with deep expertise in the development and GMP manufacturing of autologous and allogeneic cell and gene therapy (CGT) products. With a demonstrated GMP track record of more than 20 years, Cellex supports partners from preclinical development through clinical manufacturing to commercialization, serving top 10 pharma companies, leading biotech companies, innovative start-ups, and academic centers worldwide.

Cellex operates more than 2,500 m² of GMP manufacturing facilities and holds multiple manufacturing licenses covering cellular intermediates and final drug products. The company is involved in the manufacture of three approved CAR-T therapies and has produced over 8,500 CGT/ATMP batches.

Through its own apheresis center and donor database, Cellex has performed more than 50,000 cell collections for CGT and stem cell transplantation, and provides a broad portfolio of starting materials – including leukopaks, mobilized leukopaks, bone marrow, and whole blood – from both healthy donors and patients affected by specific diseases, for R&D, clinical, and commercial use. All collections are performed under GMP conditions and supplied globally. EU QP services, consulting, and GMP audits of apheresis centers worldwide complement Cellex’s offering, which is characterized by scientific expertise, quality, and flexibility